Elena Elimova, MD

Articles by Elena Elimova, MD

Zanidatamab Poised to Redefine First-Line Care in HER2+ Gastroesophageal Cancer

January 27th 2026

New trial results reveal zanidatamab significantly improves survival in HER2-positive advanced gastroesophageal adenocarcinoma, challenging existing treatment standards.

Latest Updated Articles

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Clears IND for Phase 3 Trial of iSCIB1+ in Advanced Melanoma

Tivozanib Explored in Second-Line ccRCC

How Liso-Cel Is Shifting the Treatment Paradigm of Marginal Zone Lymphoma

Future Directions in cGVHD Treatment

Amivantamab: Overcoming Resistance in RAS/BRAF Metastatic CRC